Q&A with Jason Sicklick, MD for GIST Awareness Day |
On Saturday, July 13, 2024, Moores recognized National GIST Awareness Day. Pictured above with Moores Member Dr. Jason Sicklick and Moores Director Diane Simeone, MD is Debra Melikian, who lost her son to SDH-deficient GIST and her husband to cancer. Since then, Debra has raised cancer awareness and has supported cancer research at UC San Diego.
|
New Moores Associate Director (AD) of Equity, Diversity, and Inclusion (EDI) Receives Award for Study of Fertility Preservation Among Young Cancer Patients |
Moores AD of EDI H. Irene Su, MD has been awarded a 3-year grant from the Leukemia & Lymphoma Society’s Equity in Access Research Program to support her study of fertility preservation among young blood cancer patients.
|
Stem Cell-Derived Therapy Shows Promise Against Treatment-Resistant Liver Cancer |
Researchers at UC San Diego have found that the most common form of liver cancer can be better targeted and treated using a new stem cell-derived therapy. Moores Member, Dan Kaufman MD, PhD led the study that shows why some immunotherapies have been less successful for solid tumors than for blood cancers.
|
Moores Members Inducted to the 2024 Class of American Society for Radiation Oncology (ASTRO) Fellows |
Moores Members Jona Hatangadi Gluth, MD and Jyoti Mayadev, MD have been named ASTRO Fellows for their contributions to ASTRO and the field of radiation oncology through committee work and volunteer service in the areas of research, education, patient care, and/or leadership.
|
Moores to Co-host Delivering Discoveries: Updates in Oncology CME |
Faculty from UC San Diego, SDSU, and other institutions will present the latest cancer research to improve patient outcomes, spanning all aspects of cancer, from basic science and clinical advances to community-based prevention and interception strategies.
|
|
|
Nathan L. Scott MD, Gregory A. Daniels MD, PhD and Soo J. Park, MD
|
July 16, 2024 | 4:00 p.m. to 5:30 p.m.
Zoom
|
July 17, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
August 7, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
August 9, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
September 19, 2024 | 8:30 a.m. to 6:30 p.m.
Duane Roth Auditorium (Sanford Consortium for Regenerative Medicine)
|
Testicular Cancer Awareness Foundation |
Timothy A. Masterson, MD and T. Clark Gamblin, MD, MS, MBA
|
September 19–21, 2024
Moores Goldberg Auditorium
|
|
|
FEATURED FUNDING OPPORTUNITIES |
Department of Defense, Congressionally-Directed Medical Research Program, Kidney Cancer Research Program, 2024 Funding Opportunities |
Academy of Kidney Cancer Investigators Leadership Award (New for FY24)
LOI Deadline: August 29, 2024 | 5:00 p.m. EST
Submission Deadline: September 19, 2024 | 11:59 p.m. EST
Concept Award
LOI Deadline: August 15, 2024 | 5:00 p.m. EST
Submission Deadline: September 5, 2024 | 11:59 p.m. EST
Postdoctoral and Clinical Fellowship Award
LOI Deadline: August 15, 2024 | 5:00 p.m. EST
Submission Deadline: September 5, 2024 | 11:59 p.m. EST
|
|
|
| Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells
|
Jaya Lakshmi Thangaraj PhD (Solid Tumor Therapeutics), Dan Kaufman MD, PhD (Hematologic Malignancies)
|
|
|
|
Interface-guided phenotyping of coding variants in the transcription factor RUNX1
|
Nathan D. Jayne BS (Hematologic Malignancies), Dong-er Zhang PhD (Cancer Biology and Signaling), Trey Ideker PhD (Structural and Functional Genomics), Prashant Mali PhD (Cancer Biology and Signaling), Hannah Carter PhD, MEng (Structural and Functional Genomics)
|
|
|
| Comparison of synthesized and acquired high b-value diffusion-weighted MRI for detection of prostate cancer
|
Rebecca A. Rakow-Penner MD, PhD (Solid Tumor Therapeutics), Anders M. Dale PhD (Solid Tumor Therapeutics), Tyler M. Seibert MD, PhD (Structural and Functional Genomics)
|
|
|
UCI 19-49: Phase 2 Study of Cabozantinib Combined With Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC) Who Are Not Candidates for Curative Intent Treatment
PI: Adam Burgoyne, MD, PhD
NCT: NCT04472767
|
|
|
|
